XML 37 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Discontinued Operations and Equity-Method Investment (Tables)
 3 Months Ended
Apr. 04, 2021
Business Combinations, Disposal Groups, Including Discontinued Operations, Equity Method Investments And Research And Development Arrangement [Abstract]  
Summarized Financial Information of Discontinued Operations
Components of Income from discontinued operations––net of tax:
Three Months Ended(a)
(MILLIONS)April 4,
2021		March 29,
2020
Revenues$27 $1,946 
Costs and expenses:
Cost of sales14 442 
Selling, informational and administrative expenses(8)332 
Research and development expenses1 51 
Amortization of intangible assets — 36 
Restructuring charges and certain acquisition-related costs— 15 
Other (income)/deductions––net1 70 
Pre-tax income from discontinued operations19 1,000 
Provision for taxes on income10 119 
Income from discontinued operations––net of tax$9 $881 
(a)In the three months ended April 4, 2021, Income from discontinued operations—net of tax primarily relates to the Mylan-Japan collaboration, which did not terminate until December 21, 2020 and which falls in Pfizer’s international first quarter of 2021, and adjustments to tax and legal matters directly related to the disposed Upjohn Business. In the three months ended March 29, 2020, Income from discontinued operations—net of tax relates to the Upjohn Business and the Mylan-Japan collaboration and includes the change in accounting principle in the first quarter of 2021 to MTM Accounting, which has been applied on a retrospective basis for all prior periods presented. See Note 1C.
Equity Method Investment
Summarized financial information for our equity method investee, the Consumer Healthcare JV, for the three months ending December 31, 2020, the most recent period available and for the three months ending December 31, 2019, is as follows:
Three Months Ended
(MILLIONS)December 31, 2020December 31, 2019
Net sales$3,096 $3,188 
Cost of sales(1,188)(1,811)
Gross profit$1,908 $1,377 
Income from continuing operations233 46 
Net income233 46 
Income attributable to shareholders221 37